Research Paper Volume 14, Issue 4 pp 1959—1982

Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis

Shitong Lin1,2, *, , Ting Peng1,2, *, , Yifan Meng3, , Canhui Cao4, , Peipei Gao1,2, , Ping Wu1,2, , Wenhua Zhi1,2, , Ye Wei1,2, , Tian Chu1,2, , Binghan Liu1,2, , Juncheng Wei1,2, , Xiaoyuan Huang1,2, , Wencheng Ding1,2, , Cai Cheng5, &, ,

  • 1 Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
  • 2 Department of Gynecologic Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
  • 3 Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
  • 4 Department of Reproductive Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, China
  • 5 Division of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
* Equal contribution

Received: September 27, 2021       Accepted: January 4, 2022       Published: February 26, 2022
How to Cite

Copyright: © 2022 Lin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Paclitaxel remains the first-line chemotherapy regimen for many malignant tumors. However, prognosis and adverse events under different dosing regimens (one-week versus three-week treatment) remain contradictory in many randomized controlled trials (RCTs). Here, we performed a comprehensive meta-analysis to measure the efficacy and toxicities of these two dosing regimens. Four databases were systematically retrieved. RCTs comparing two paclitaxel dosing regimens for advanced malignant tumors with assessable outcomes (e.g., overall survival (OS), progression-free survival (PFS), toxicities, response rates) were included. In total, 19 eligible RCTs involving 9 674 patients were included. Meta-analysis of pan-cancers revealed that weekly paclitaxel treatment was more beneficial regarding PFS compared to three-week paclitaxel treatment (hazard ratio (HR) = 0.90, 95% confidence interval (CI) = 0.82–0.99, P = 0.02). Nevertheless, there was no significant difference in terms of OS between the two dosing regimens (HR = 0.98, 95%CI = 0.91–1.06, P = 0.62) or other tested subgroups. In terms of serious adverse events, grade 3 or 4 (G3/4) neutropenia, G3/4 febrile neutropenia, G3/4 arthritis, and G3/4 alopecia occurred less often under weekly paclitaxel treatment. In summary, Weekly paclitaxel treatment demonstrates better PFS and fewer chemotherapy-induced hematological and non-hematological toxicities compared to the three-week paclitaxel regimen.


RCTs: randomized controlled trials; OS: overall survival; PFS: progression-free survival; G3/4: grade 3 or 4; CI: confidence interval; HR: hazard ratio; OR: odds ratio; ORR: overall response rate; CRR: complete response rate; PRR: partial response rate; DDR: dose-density ratio; AUC: area under the curve; NCCN: National Comprehensive Cancer Network; SE: standard error; MESH: the Medical Subject Heading.